Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Limnophila sessiliflora

ABSTRACT: Limnophila sessiliflora Genome sequencing and assembly

PROVIDER: PRJNA814836 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18313725_1.fastq.gz	Fastqsanger.gz
	SRR18313725_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Lacunisphaera limnophila strain:IG16b

Project description:Lacunisphaera limnophila strain:IG16b Genome sequencing and assembly

| PRJNA319155 | ENA

Limnophila sessiliflora

Project description:Limnophila sessiliflora overview

| PRJNA846469 | ENA

Sandarakinorhabdus limnophila

Project description:Sandarakinorhabdus limnophila overview

| PRJNA185939 | ENA

Sandaracinomonas limnophila strain:FSY-15

Project description:Sandaracinomonas limnophila strain:FSY-15 Genome sequencing and assembly

| PRJNA512567 | ENA

Membrane proteins of Planctopirus limnophila

Project description:Bacteria of the phylum Planctomycetes have been postulated to be the ‘missing link’ between prokaryotes and eukaryotes. Although phylogenetically the Planctomycetes were grouped into Gram-negative bacteria, it has been reported that they have no outer membrane. Here we present 1D-gel-LC/MS/MS based proteomics data of Planctopirus limnophila membraneswhich in combination with super resolution light microscopy, cryo electron tomography and bioinformatics suggest an altered Gram-negative cell plan for Planctopirus limnophila.

2017-04-18 | PXD005738 | Pride

Planctopirus limnophila strain:Mgru023

Project description:Planctopirus limnophila strain Mgru023

| PRJNA924961 | ENA

Sandarakinorhabdus limnophila DSM 17366

Project description:Sandarakinorhabdus limnophila DSM 17366

| PRJNA185658 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc